Literature DB >> 10935272

Avian mycoplasmosis (Mycoplasma gallisepticum).

S Levisohn1, S H Kleven.   

Abstract

Mycoplasma gallisepticum is the most economically significant mycoplasma pathogen of poultry, and has a world-wide distribution. In common with other mycoplasmas, M. gallisepticum is minute in size with minimal genetic information and with a total lack of a bacterial cell wall. These properties are reflected in a high degree of interdependence between M. gallisepticum and the host animal, and in the fastidious nature of the organism in vitro. Strains of M. gallisepticum differ markedly with respect to important biological properties such as pathogenicity, infectivity, tissue tropism and transmissibility. In addition, phenotypic variation of major surface antigens occurs at high frequency, which is a probable explanation for chronic infection by M. gallisepticum despite a strong immune response. Infection with M. gallisepticum has a wide variety of clinical manifestations, but even in the absence of overt clinical signs, the economic impact may be significant. The most dramatic disease presentation of M. gallisepticum is chronic respiratory disease in meat-type birds, often as one of several aetiological agents in a multi-factorial disease complex. Transmission of M. gallisepticum in ovo from infected breeder birds to progeny is the major route of dissemination of the infection, and is the prime consideration for international trade. In most countries, control programmes for M. gallisepticum are based on maintaining commercial breeding stock free of infection. In instances where control of M. gallisepticum infection is not feasible, vaccination, especially with newly developed live M. gallisepticum vaccines, is being evaluated as an option. Major advances in diagnostic methods have been made in recent years. Control programmes have been based on serological methods, with screening for infection usually accomplished by the slide plate agglutination (SPA) test or by enzyme-linked immunosorbent assay. Further serological testing and/or demonstration of the presence of the organism must be used to confirm SPA suspected positive tests. In principle, detection of the presence of the M. gallisepticum organism can be by isolation of the organism or detection of the deoxyribonucleic acid by molecular methods. Polymerase chain reaction represents a rapid and sensitive alternative to traditional culture methods, which require time-consuming specialised techniques. The development of molecular typing methods affords new opportunities for epidemiological studies and identification of reservoirs of infection.

Entities:  

Mesh:

Year:  2000        PMID: 10935272

Source DB:  PubMed          Journal:  Rev Sci Tech        ISSN: 0253-1933            Impact factor:   1.181


  39 in total

1.  Molecular variability of the adhesin-encoding gene pvpA among Mycoplasma gallisepticum strains and its application in diagnosis.

Authors:  T Liu; M García; S Levisohn; D Yogev; S H Kleven
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

2.  Transcriptome analysis reveals novel regulatory mechanisms in a genome-reduced bacterium.

Authors:  Pavel V Mazin; Gleb Y Fisunov; Alexey Y Gorbachev; Kristina Y Kapitskaya; Ilya A Altukhov; Tatiana A Semashko; Dmitry G Alexeev; Vadim M Govorun
Journal:  Nucleic Acids Res       Date:  2014-10-31       Impact factor: 16.971

3.  Correlates of immune protection in chickens vaccinated with Mycoplasma gallisepticum strain GT5 following challenge with pathogenic M. gallisepticum strain R(low).

Authors:  Mohammed A Javed; Salvatore Frasca; Debra Rood; Katharine Cecchini; Martha Gladd; Steven J Geary; Lawrence K Silbart
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Occurrence of concurrent infectious diseases in broiler chickens is a threat to commercial poultry farms in Central Ethiopia.

Authors:  Mersha Chanie; Tamiru Negash; Samuel Bekele Tilahun
Journal:  Trop Anim Health Prod       Date:  2009-02-21       Impact factor: 1.559

5.  Transcriptional Profiling of the Chicken Tracheal Response to Virulent Mycoplasma gallisepticum Strain Rlow.

Authors:  J Beaudet; E R Tulman; K Pflaum; X Liao; G F Kutish; S M Szczepanek; L K Silbart; S J Geary
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

6.  In vivo pharmacokinetic/pharmacodynamic profiles of valnemulin in an experimental intratracheal Mycoplasma gallisepticum infection model.

Authors:  Xia Xiao; Jian Sun; Tao Yang; Xi Fang; Dong Wu; Yan Q Xiong; Jie Cheng; Yi Chen; Wei Shi; Ya-Hong Liu
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

7.  Behaviors and Energy Source of Mycoplasma gallisepticum Gliding.

Authors:  Masaki Mizutani; Makoto Miyata
Journal:  J Bacteriol       Date:  2019-09-06       Impact factor: 3.490

8.  Development of Molecular Methods for Rapid Differentiation of Mycoplasma gallisepticum Vaccine Strains from Field Isolates.

Authors:  Kinga M Sulyok; Zsuzsa Kreizinger; Katinka Bekő; Barbara Forró; Szilvia Marton; Krisztián Bányai; Salvatore Catania; Christine Ellis; Janet Bradbury; Olusola M Olaogun; Áron B Kovács; Tibor Cserép; Miklós Gyuranecz
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

9.  Detection and differentiation of avian mycoplasmas by surface-enhanced Raman spectroscopy based on a silver nanorod array.

Authors:  Suzanne L Hennigan; Jeremy D Driskell; Naola Ferguson-Noel; Richard A Dluhy; Yiping Zhao; Ralph A Tripp; Duncan C Krause
Journal:  Appl Environ Microbiol       Date:  2011-12-30       Impact factor: 4.792

10.  Differential Response of the Chicken Trachea to Chronic Infection with Virulent Mycoplasma gallisepticum Strain Ap3AS and Vaxsafe MG (Strain ts-304): a Transcriptional Profile.

Authors:  Glenn F Browning; Nadeeka K Wawegama; Sathya N Kulappu Arachchige; Neil D Young; Pollob K Shil; Alistair R Legione; Anna Kanci Condello
Journal:  Infect Immun       Date:  2020-04-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.